Lipinutragen: InnovAction for the market of molecular medicine

Dr. Carla Ferreri, Company co-founder &

Dr. Arianna Salati, CEO

• MOLECULAR BASIS Organic synthesis, kinetics, mechanisms

• “STRESS-OMICS” Stress of biological molecules (DNA, proteins, lipids): analytical methodologies and biomimetic models

• MOLECULAR MEDICINE BIOMARKER DISCOVERY (cyclopurines, trans lipids, desulfurated peptides and proteins), transfer to biology-medicine-biotechnology

• MOLECULAR BASIS Organic synthesis, kinetics, mechanisms

• “STRESS-OMICS” Stress of biological molecules (DNA, proteins, lipids): analytical methodologies and biomimetic models

• MOLECULAR MEDICINE BIOMARKER DISCOVERY (cyclopurines, trans lipids, desulfurated peptides and proteins), transfer to biology-medicine-biotechnology

Focus on this compartment: cells cannot exist without

MEMBRANES that are necessary for ORGANIZATION and

FUNCTIONING

MEMBRANE REACTIVITY: The UNSATURATED FATTY ACID

are REACTIVE to STRESS

We envisaged it as a new field of chemical biology

H O

O 9 Oleic acid

9c–C18:1

H O

O 5 8 1 1 1 4

H O

O 9 1 2 Linoleic acid

Arachidonic acid

9c,12c–C18:2

5c,8c,11c,14c–C20:4

9

1 2

9

1 2

RS•

Lipid isomerization (MUFA & PUFA)

Dramatic change of the NATURAL geometry

Biomimetic model • Liposomes as models for

pharmacological, nutraceutical and biological studies

• Studied by the COST Action CM1201 -

Leader position and coordination activity of 20 research groups in the Working group (WG3) of the Action (http://www.biomimetic-rad-chem.eu)

Membrane stress, signaling and defences

Vol 114, pag. 255-284 (2014)

• MOLECULAR BASIS Competitive isomerization and peroxidation – Role of antioxidant synergies

• “STRESS-OMICS” Analytical and molecular libraries for recognition in biological fluids New models of cellular stress

• MOLECULAR MEDICINE Development of a new discipline regarding lipids

Lipidome monitoring for the MEMBRANE fatty acid asset

S - M - P

Response to stress and stimuli NEW INSIGHTS IN BIOLOGICAL AND

PHARMACOLOGICAL PATHWAYS

DIET METABOLISM

LIPIDOMICS in humans 9 Children atopic dermatitis (TRANS) Chem. Phys. Lipids 2002, Lipids 2005 9 Longevity - Centenarian offspring (TRANS) Int. J. Cell Biochem. 2008, Rejuven. Res. 2008 9 Human atrial fibrillation J. Interv. Card. Electrophysiol. 2010 9 Children autism, PLoS ONE, 2013 9 Celiac disease, Br. J. Nutr 2014 9 Man infertility, submitted 2015 LIPIDOMICS in cells 9 Leukemia cell lines (TRANS) Free Radic Biol Med 2005 9 Beta pancreatic cell lines, Diabetes 2011 9 Neuroblastoma cell lines, PLoS ONE 2013 9 Bleomycin treated cell, Org. Biomol. Chem. 2015

Lipidomics in animals 9 Rats fed a trans-free diet Free Radic Biol Med 2005 9 Environmental radiation to animals Rad. Res. 2012 9 Sportive rats Lipids in Health and Disease, 2012

Erythrocyte membrane lipidome

All important fatty acids represented

(arachidonic, omega-3, saturated FA, trans FA)

Representative of other tissues

CHOOSE the MATURE ERYTHROCYTE for the best REPORTER capacity (original protocol – high-throughput device)

SELECT A FATTY ACID CLUSTER (12 ELEMENTS) TO DESCRIBE THE MEMBRANE BALANCE (MEMBRANE UNBALANCE INDEX MUI – PATENT WO2010023698A1) EXPERT REV. MOL. DIAGN. 2012, 12, 767-780)

Born in Dec. 2005 as CNR spin off company

www.lipinutragen.it Co-founders: Carla Ferreri and Chryssostomos Chatgilialoglu + 2 private partners Fund raising: private funds from the 4 partners

In 2011-2012 the partners changed and now they are: FERRERI 40% CHATGILIALOGLU 50% MARANINI 10%

In 2011 it was proposed to CNR to enter as partner

No INTEREST

Is the first italian company, born as CNR spin-off, applying in  a  “real”  market,  Research, Innovation and Internationalization

• Human first • Research • Disruptive innovation • Quality • Ethics • Devotion

“Life  Balance”  through Membrane Balance

To become  the  world’s  pioneer and leader in

nutrilipidomic research and development

Vision Mission Value

Strategic development

Market preparation

and scientific background

Market survey

Development scientific background

Dec 2005- 2006

FUND raising

Development Lipidomic Laboratory

R&D and Marketing reinforce

Launch Expansion and

Market development

ROBOTICS: Highthroughput development and brand

Development FAT PHARMACY®

2012-13

LIPIDOMIC DIET software

CME courses Formation

2007-11

Pre-Launch Product development

Start of sales EARLY ADOPTERS

First business model: Fat Profile®

Nutragenika line PARTNERSHIPS

Lipidomic profile data base and software

Patent and trade marks

2014-18

Post-Launch Consolidating client portfolio

Further expansion

International Market GREECE SPAIN

POLAND

Nutrilipidomics: functional foods

International Research program

(EUROSTARS – H2020) FIRST FUNDING from INSTITUTIONS (EU)

Overcome the DEATH VALLEY

End of the spin-off status

2012 2013 2014

BILLING COMPANY

EMPLOYEES 9

5 3

BOLOGNA

ATHENS

BILBAO

Lodz

Lipinutragen’s idea of expansion in Europe

3 years

9 Entrepreneurship founded by researchers, incubated in institutions/universities

9 Entering the market to bring innovation made of scientific advancements in life sciences (SCIENCE ETHICS)

EXPANSION of the IDEA to bring SCIENCE to MARKET

MOLECULAR DIAGNOSTICS

PREVENTION & QUALITY LIFE

HUMAN FIRST RESEARCH & INNOVATION

NUTRA - THERAPY

LIPINUTRAGEN, DIVISIONS AND CUSTOMERS

BE ETHICS QUALITY & DEVOTION

FATHARMACY – PREVENTION AND QUALITY LIFE

CUSTOMERS: 92 SELECTED PHARMACIES AS CUSTOMERS MORE THAN 150 ANALYSES per MONTH MORE THAN 4.400 PERSONS ANALYZED IN 3 YEARS(2012-2014)

ACTIVITIES 2014 2 CME COURSES FOR PHARAMCISTS 3 COMMUNICATION TRAINING DISLOCATED COURSES SOFTWARE DEDICATED IN EACH OF 92 PHARMACIES CONSULTING BOARD OF PHARMACISTS TRAINING AND AWARENESS PAPERS, CAMPAIGN and web strategy

FATPROFILE – MOLECULAR DIAGNOSIS

CUSTOMERS 250 SPECIALISTS: MEDICAL DOCTORS AND NUTRITIONISTS MORE THAN 200 ANALYSES per MONTH MORE THAN 4.800 PERSONS ANALYZED IN 4 YEARS (2011-2014)

ACTIVITIES 3 NATIONAL CME COURSES PER YEAR CASE HISTORY AND CUSTOMER DATABASE STUDY INTERNAL RESEARCH PROJECT (ON GOING) Co-funded by Lipinutragen & Medical partners and published

• Ospedale Maggiore – Autism

• IRCCS _ Istituto delle Scienze Neurologiche di Bologna - Duchenne

• De Bellis – Celiac disease

• The Hebrew University – Diabetes

NUTRAGENIKA, PESONALIZED NUTRITIONAL THERAPY

OBJECTIVE TO PROVIDE THE MARKET WITH HIGH QUALITY PRODUCTS RESULT OF STUDIES THAT INVOLVED ABOUT 9.000 ANALYSES DELIVERED: 4 NUTRACEUTICAL PRODUCTS SALES TURNOVER OF ABOUT 200.000 € MORE THAN 10.000 UNITS SOLD IN 2014

FUNCTIONAL FOODS NUTRANUT:  NUT’S  CREAM  WITH  CACAO,  EV  OLIVE  OIL  AND LINESEEDS VERY LOW SATURED FATTY ACID CONTENT AND BALANCED W3-W6 CONTENT

LIPINUTRAGEN & CNR 2015 -2018 EU PROJECTS

Project: E!7348 LIPIDOMEL Title: New nutritional approach to develop a dietary ingredient against excess weight- and oxidative stress-induced disorders Partners: BIONOV (France), LIPINUTRAGEN (Italy), ISOF-CNR (Italy) Scientist in charge: Dr. Carla Ferreri Period: Apr. 2014 – Mar. 2017

Marie Sklodowska Curie Actions – Innovation Training Networks (ITN)-ETN- H2020 Title: Click Chemistry for future gene therapies to benefit citizens, researches and industry Responsible: dr. Valentina Sunda Period: 01.01.2015 – 31.12.2018

ISOF – CNR Scientist in charge: Dr. Carla Ferreri 258.000€ 100% EC FUNDS (1 PhD student)

258.000€ 100% EC FUNDS (1 PhD student)

160.000€ - 50% LIPINUTRAGEN – 50% MIUR 160.000€ - 50% CNR (salaries of permanent researchers) – 50% MIUR

APPLICATIVE RESEARCH APPROCH

LIPINUTRAGEN & CNR SYNERGY

APPLICATIVE R&D APPROACH

FOCUS ON REAL MARKET

SCIENTIFIC BASIS for RESEARCH AND DEVELOPEMENT

NATIONAL AND INTERNATIONAL PROJECTS

GRAZIE!!

If you like, you can taste it